Warning
: your browser is no longer supported.
CLICK HERE
to review the supported browser list.
CLICK HERE
to download a PDF version of this report to read and/or print.
2025 Proxy Statement
Menu
Close
Select Document
✔
{hosting_shortdoctitlestripped}
✔
{doc1_shortdoctitlestripped}
✔
{doc2_shortdoctitlestripped}
✔
{doc3_shortdoctitlestripped}
✔
{doc4_shortdoctitlestripped}
✔
{doc5_shortdoctitlestripped}
✔
{doc6_shortdoctitlestripped}
✔
{doc7_shortdoctitlestripped}
✔
{doc8_shortdoctitlestripped}
✔
{doc9_shortdoctitlestripped}
✔
{doc10_shortdoctitlestripped}
✔
{doc11_shortdoctitlestripped}
✔
{doc12_shortdoctitlestripped}
✔
{doc13_shortdoctitlestripped}
✔
{doc14_shortdoctitlestripped}
✔
{doc15_shortdoctitlestripped}
2025 Proxy Statement
Purpose Blueprint
Table of Contents
A Letter from Pfizer's Chairman & Chief Executive Officer
A Message from Pfizer's Lead Independent Director
Notice of 2025 Annual Meeting and Proxy Statement
Our Business and Strategy
Item 1 - Election of Directors
Criteria for Board Membership
Selection of Candidates
Director Independence
Our 2025 Director Nominees
Director Nominees
Governance
Overview
Governance Materials Available on Our Website
The Board's Leadership Structure
The Board's Role in Risk Oversight
The Board's Role in Succession Planning
Evaluation of Board Effectiveness
Board and Committee Information
Governance Committee Report
Regulatory and Compliance Committee Report
Investor Outreach
Public Policy Engagement and Political Participation
Pfizer Policies on Business Conduct
Other Governance Practices and Policies
Non-Employee Director Compensation
2024 Director Compensation Table
Securities Ownership
Beneficial Owners
Delinquent Section 16(a) Reports
Item 2 - Ratification of Selection of Independent Registered Public Accounting Firm
Audit and Non-Audit Fees
Audit Committee Report
Item 3 - 2025 Advisory Approval of Executive Compensation
2024 Advisory Vote on Executive Compensation
2024 Pay-for-Performance
2025 Advisory Vote on Executive Compensation
Compensation Committee Report
Executive Compensation
Compensation Discussion and Analysis
Executive Summary
Compensation Tables
Financial Measures
Shareholder Proposals
Item 4 - Shareholder Vote Regarding Golden Parachutes
Item 5 - Issue a Report Evaluating the Risks Related to Religious Discrimination Against Employees
Annual Meeting Information
Annual Meeting
Voting
Proxy Materials
Other Questions
Other Business
Submitting Proxy Proposals and Director Nominations for the 2026 Annual Meeting
Corporate and Shareholder Information
Meet our Director Nominees
Help & Features
Download PDF
Downloads
Company Home
Share
Print
Clickable Index
Thumbnails
Accessibility Features
Help
Menu
Zoom In
Zoom Out
Zoom In
Help
Help
TOC
TOC
PDF
PDF
Home
Home
Home
Home
Home
Zoom Out
Home
Home
Home
Home
Print
Print
Print
Clickable Index
Clickable Index
Thumbnails
Thumbnails
Help
Help
Unpin Menu Bar
Pin Menu Bar
Go to previous page
Go to previous page
Go to previous page
Go to previous page
Go to next page
Go to next page
Go to next page
Page 3 of 113
Single Page View
Double Page View
Table of Contents
A Letter from Pfizer’s Chairman & Chief Executive Officer
i
A Message from Pfizer’s Lead Independent Director
iv
Notice of 2025 Annual Meeting and Proxy Statement
vi
Our Business and Strategy
1
Item 1 — Election of Directors
6
Criteria for Board Membership
6
Selection of Candidates
6
Director Independence
7
Our 2025 Director Nominees
8
Director Nominees
11
Governance
18
Overview
18
Governance Materials Available on Our Website
18
The Board’s Leadership Structure
18
The Board’s Role in Risk Oversight
19
The Board’s Role in Succession Planning
20
Evaluation of Board Effectiveness
21
Board and Committee Information
21
Governance Committee Report
24
Regulatory and Compliance Committee Report
25
Investor Outreach
26
Public Policy Engagement and Political Participation
29
Pfizer Policies on Business Conduct
31
Other Governance Practices and Policies
32
Non-Employee Director Compensation
33
2024 Director Compensation Table
34
Securities Ownership
35
Beneficial Owners
36
Delinquent Section 16(a) Reports
36
Item 2 — Ratification of Selection of Independent Registered Public Accounting Firm
37
Audit and Non-Audit Fees
38
Audit Committee Report
39
Item 3 — 2025 Advisory Approval of Executive Compensation
40
2024 Advisory Vote on Executive Compensation
40
2024 Pay-for-Performance
40
2025 Advisory Vote on Executive Compensation
41
Compensation Committee Report
42
Executive Compensation
43
Compensation Discussion and Analysis
43
Executive Summary
44
Compensation Tables
70
Financial Measures
92
Shareholder Proposals
93
Item 4 — Shareholder Vote Regarding Golden Parachutes
93
Item 5 — Issue a Report Evaluating the Risks Related to Religious Discrimination Against Employees
96
Annual Meeting Information
98
Annual Meeting
98
Voting
99
Proxy Materials
102
Other Questions
103
Other Business
103
Submitting Proxy Proposals and Director Nominations for the 2026 Annual Meeting
104
...Previous
Continue...
WARNING: JavaScript is disabled.
CLICK HERE
for help.
Click here
for a list of supported browsers.